Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00088179
Recruitment Status : Completed
First Posted : July 23, 2004
Last Update Posted : February 22, 2018
Procter and Gamble
Information provided by:
Alexion Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2005
  Actual Study Completion Date : October 2005
  Certification/Extension First Submitted : February 15, 2017